📈 Jumpstart Signal Watchlist — August 17, 2026

🏢 What they do: Mitek Systems, Inc. (MITK) specializes in digital identity verification, authentication, biometrics, mobile image capture, and fraud detection solutions. Its enterprise-grade platform enables secure onboarding, check deposits, transaction protection, and real-time defense against threats like deepfakes and synthetic fraud for banks, fintechs, and other organizations.
- 🎯 Current $18.53 is 8% below 3yr high $20.14 · ⏳ SMA200 $13.62 (current price $18.53 is above) · 💰 Market Cap $836M
- MITK shows decent technicals supported by positive sentiment.

💎 Quality (Q): 48/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 240% (>20%); Revenue growth 18% (>15%); Low LT D/E 0.20 (<1.0); PEG ratio 0.16 (<1.5).
⏰ Entry (E): 0/20
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Mitek Appoints Aaron Seyler as Chief Revenue Officer — Business Wire.
🤖 Mitek named Aaron Seyler as Chief Revenue Officer effective August 17, 2026, a leadership move aimed at strengthening go-to-market execution. The appointment is likely positive because it signals management investment in revenue growth.
✅ Mitek Reports Fiscal Third Quarter Revenue of $54.0 Million, Up 18% Year-Over-Year; Raises Full-Year Outlook — Business Wire.
🤖 Mitek reported fiscal Q3 revenue of $54.0 million, with record Fraud & Identity SaaS revenue, and raised full-year fiscal 2026 guidance. Beating expectations and lifting outlook are both supportive for the stock.
✅ Mitek beats Q3 2026 estimates, shares jump after hours — Investing.com.
🤖 The article says Mitek topped analyst expectations with adjusted EPS of $0.34 and revenue of $54.04 million, and that the company raised fiscal 2026 outlook. Better-than-expected results and higher guidance are positive for MITK.
🍭 Bonus (B): 10/10 — Computer Peripheral Equipment (Technology sector)

🏢 What they do: MeiraGTx Holdings plc is a clinical-stage genetic medicines company that develops gene therapies and other genetic medicine platforms for both rare and more common diseases. Its work includes programs in eye diseases, Parkinson’s disease, and radiation-induced dry mouth, along with its riboswitch technology for controlled delivery of biologic therapies.
- 🎯 Current $13.77 is 6% below 3yr high $14.66 · ⏳ SMA200 $9.31 (current price $13.77 is above) · 💰 Market Cap $1.3B
- MGTX shows decent technicals supported by positive sentiment.

💎 Quality (Q): 38/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 456% (>20%); PEG ratio 0.04 (<1.5).
⏰ Entry (E): 3/20
- 🔔 Strong above EMA21 (8.5%)
- 🔔 Strong above EMA50 (14.6%)
- 📈 RSI at 65 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Johnson & Johnson Takes $89.72 Billion Position in MeiraGTx Holdings PLC — MarketBeat.
🤖 This item reports a very large new institutional position in MGTX, which can signal confidence from a major healthcare investor. It is supportive for sentiment, although the reported value appears unusual and the article is still framed as a filing-based ownership update.
✅ FY2026 EPS Estimates for MeiraGTx Increased by HC Wainwright — MarketBeat.
🤖 HC Wainwright raised its FY2026 EPS estimate and kept a Buy rating with a $20 target, while other analyst commentary in the item remains broadly constructive. Higher earnings expectations and a positive rating are favorable for the stock.
❌ MeiraGTx (NASDAQ:MGTX) CFO Richard Giroux Sells 56,000 Shares — MarketBeat.
🤖 The filing shows a sizable insider sale by the CFO, which can be a mild negative signal for market sentiment. The article also notes the company recently missed revenue expectations, adding some caution despite the earnings beat.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Bioventus Inc. is a global medical device company that develops and commercializes clinically proven, minimally invasive products to relieve pain and address musculoskeletal challenges by enhancing the body's natural healing process .
- 🎯 Current $13.88 is 9% below 3yr high $15.26 · ⏳ SMA200 $9.17 (current price $13.88 is above) · 💰 Market Cap $938M
- BVS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 327% (>20%); ROE 24% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.06 (<1.5).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA50 (15.3%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (60) — BEARISH
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Bioventus' (BVS) "Overweight" Rating Reiterated at Cantor Fitzgerald — MarketBeat.
🤖 Cantor Fitzgerald reiterated an Overweight rating and kept a $15 price target, signaling continued analyst confidence in upside for BVS. The note also cited a favorable consensus view across covering analysts.
✅ Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Brokerages — MarketBeat.
🤖 The article says Bioventus has a consensus Buy rating from six analysts, with an average price target above the current share price. That combination is typically supportive for sentiment around the stock.
⚪️ Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth — Yahoo Finance / Zacks Equity Research.
🤖 This is an earnings preview rather than a results or guidance update, and it mainly summarizes expectations for the upcoming quarter. It does not provide new company-specific financial information that would clearly move the stock on its own.
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: BioCryst Pharmaceuticals is a biotechnology company that develops and commercializes medicines for hereditary angioedema (HAE) and other rare diseases. Its key products include ORLADEYO for preventing HAE attacks and RAPIVAB for treating influenza, and it is also advancing additional rare-disease drug candidates.
- 🎯 Current $9.94 is 11% below 3yr high $11.19 · ⏳ SMA200 $8.36 (current price $9.94 is above) · 💰 Market Cap $2.5B
- BCRX shows decent technicals supported by positive sentiment.

💎 Quality (Q): 26/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1400% (>20%); Revenue growth 34% (>15%).
⏰ Entry (E): 6/20
- 🔔 SMA20/SMA50 bullish crossover
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 55 in healthy mid-range
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ BioCryst Pharmaceuticals Q2 Earnings Call Highlights — Finance Yahoo.
🤖 BioCryst reported strong Q2 results, including 10% year-over-year ORLADEYO revenue growth to $158.2 million and maintained full-year ORLADEYO revenue guidance. The company also raised 2026 total revenue guidance while trimming operating-cost guidance, which is favorable for the stock.
✅ BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Rating of "Moderate Buy" by Brokerages — MarketBeat.
🤖 The brokerage consensus remained at Moderate Buy, with eight buy ratings and four hold ratings and a $20.80 average price target. That generally supportive analyst backdrop is positive for sentiment toward BCRX.
⚪️ Royal Bank Of Canada Issues Pessimistic Forecast for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Price — MarketBeat.
🤖 RBC lowered its price target on BCRX to $13 from $14 but kept an outperform rating. The cut is mildly negative on the margin, but the continued positive rating and still-large implied upside keep the overall impact mixed.
⚪️ Wedbush Issues Pessimistic Forecast for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price — MarketBeat.
🤖 Wedbush issued an outperform rating while discussing the stock alongside recent analyst activity. Because the article does not report a new company-specific operational development, the effect on the stock is limited and mostly sentiment-driven.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Quad/Graphics is a marketing experience company that provides print and related marketing services. Its offerings include printing for magazines, catalogs, direct mail, packaging, and retail inserts, along with creative, media, data, and digital marketing services.
- 🎯 Current $10.12 is 7% below 3yr high $10.85 · ⏳ SMA200 $7.08 (current price $10.12 is above) · 💰 Market Cap $483M
- QUAD shows decent technicals supported by positive sentiment.

💎 Quality (Q): 41/60
- 🏦 Low drawdown (14.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; PEG ratio 0.99 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (5.6%)
- 🔔 Strong above EMA50 (13.9%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 63 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Quad Reports Second Quarter and Year-to-Date 2026 Results — PR Newswire.
🤖 Quad reported Q2 2026 EPS of $0.24, beating expectations, and reaffirmed full-year 2026 guidance. The company also highlighted new client wins, packaging expansion, and strong capital return activity, which are supportive for the stock.
✅ Quad Graphics, Inc (NYSE:QUAD) Given Consensus Rating of "Buy" by Analysts — MarketBeat.
🤖 Analyst sentiment remained constructive, with the consensus rating described as Buy and multiple firms maintaining or upgrading their views. Positive analyst coverage and higher price targets can support investor sentiment toward QUAD.
⚪️ Quad Graphics, Inc Declares Quarterly Dividend of $0.10 — MarketBeat.
🤖 Quad announced a regular quarterly dividend, which is generally stable capital-return news rather than a major new catalyst. The announcement supports shareholder yield but does not materially change the company’s operating outlook.
🍭 Bonus (B): 0/10 — Printing & Publishing

🏢 What they do: Hewlett Packard Enterprise (HPE) is an enterprise technology company that provides compute, storage, networking, and software solutions designed for hybrid IT environments and AI infrastructure.
- 🎯 Current $57.61 is 4% below 3yr high $59.82 · ⏳ SMA200 $30.95 (current price $57.61 is above) · 💰 Market Cap $76.2B
- HPE shows decent technicals supported by positive sentiment.

💎 Quality (Q): 49/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 154% (>20%); Revenue growth 40% (>15%); Low LT D/E 0.86 (<1.0); PEG ratio 0.34 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (9.6%)
- 🔔 Strong above EMA50 (20.5%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 66 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ HPE Stock Hits a 52-Week High: Is It Too Late to Buy After the ... — Yahoo Finance.
🤖 Morgan Stanley upgraded HPE to Overweight and set a $69 target after the stock hit a fresh 52-week high. The article frames the move as support for bullish sentiment, though it also notes the stock has already rallied sharply this year.
✅ HPE wins approval for DOJ settlement in Juniper deal — Seeking Alpha.
🤖 A judge approved HPE’s settlement with the DOJ over the Juniper Networks acquisition, removing a major regulatory obstacle. That lowers deal uncertainty and is strategically positive for HPE’s networking business.
✅ HPE Stock Jumps After Morgan Stanley Upgrade — Analyst Admits ‘We’ve Been On The Wrong Side’ Of The Enterprise Hardware Trade — Yahoo Finance.
🤖 Morgan Stanley upgraded HPE to Overweight, citing a more constructive view on enterprise hardware and attractive risk/reward. The upgrade and higher conviction on earnings power are supportive for the stock.
🍭 Bonus (B): 10/10 — Computer & Office Equipment (Technology sector)

🏢 What they do: Avnet, Inc. is a global distributor of electronic components and a technology solutions provider that supports engineers, entrepreneurs, and startups in taking tech projects from idea and design to prototype and mass production.
- 🎯 At/above 3yr high $98.63 (current $98.63) · ⏳ SMA200 $68.25 (current price $98.63 is above) · 💰 Market Cap $8.1B
- AVT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (13.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1578% (>20%); Revenue growth 48% (>15%); Low LT D/E 0.39 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (6.1%)
- 🔔 Strong above EMA50 (10.8%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 66 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ GSA Capital Partners LLP Invests $2.06 Million in Avnet, Inc. $AVT — MarketBeat.
🤖 This is mildly positive because it highlights continued institutional interest in AVT and notes that analyst sentiment remains favorable overall. The article also references upgraded price targets and the company’s strong recent earnings backdrop.
✅ Avnet (NASDAQ:AVT) Hits New 52-Week High on Better-Than-Expected Earnings — MarketBeat.
🤖 This is positive because Avnet posted earnings and revenue well above expectations, and the stock reached a new 52-week high afterward. The article suggests investors reacted favorably to the strong quarterly results and raised outlook.
⚪️ Amundi Reduces Stock Position in Avnet, Inc. $AVT — MarketBeat.
🤖 This is neutral because the main item is an institutional position change rather than a direct operational catalyst. The article also mixes in analyst upgrades and a strong stock price backdrop, which softens the impact of the stake reduction.
🍭 Bonus (B): 0/10 — Electronic Parts - Wholesale

🏢 What they do: TechnipFMC plc (NYSE: FTI) is a technology provider to the traditional and new energy industries, delivering fully integrated projects, products, and services through its two main segments: Subsea and Surface Technologies.
- 🎯 At/above 3yr high $79.76 (current $79.76) · ⏳ SMA200 $61.52 (current price $79.76 is above) · 💰 Market Cap $31.3B
- FTI shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 41% (>20%); ROE 36% (>15%); Low LT D/E 0.12 (<1.0); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (8.4%)
- 🔔 Strong above EMA50 (11.1%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 69 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ TechnipFMC Awarded Flexible Pipe Contract for Azule's West Hub Tails Project — Yahoo Finance / Business Wire.
🤖 TechnipFMC said it won a significant flexible pipe contract for Azule Energy’s West Hub Tails project, and the award will add to third-quarter 2026 inbound orders. New contract wins are favorable for revenue visibility and backlog growth.
✅ TechnipFMC Announces Second-Quarter 2026 Results — Business Wire.
🤖 TechnipFMC reported strong Q2 2026 results, including $2.7 billion in inbound orders, $488 million in free cash flow, and performance tracking toward the high end of guidance. The release also included a quarterly dividend declaration, which reinforces capital return and operational strength.
✅ TechnipFMC Q2 2026 slides: subsea margins hit record, pipeline grows — Investing.com.
🤖 The article highlighted better-than-expected Q2 earnings and revenue, record subsea margins, and management confidence in full-year inbound order targets. Even though the shares fell on the day, the underlying operating and guidance trends were favorable for the stock.
🍭 Bonus (B): 0/10 — Oil & Gas Field Machinery

🏢 What they do: CareDx, Inc. is a precision medicine company focused on transplant patients. It develops diagnostics, digital health tools, lab products, and patient support services to help monitor care before and after organ transplantation.
- 🎯 Current $46.38 is 3% below 3yr high $47.85 · ⏳ SMA200 $22.62 (current price $46.38 is above) · 💰 Market Cap $2.4B
- CDNA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1394% (>20%); Revenue growth 52% (>15%); ROE 26% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (9.3%)
- 🔔 Strong above EMA50 (29.2%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 67 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ CareDx Announces Second Quarter 2026 Financial Results — Yahoo Finance / Business Wire.
🤖 CareDx reported second-quarter revenue growth of 52% to $132 million and raised full-year 2026 guidance for both revenue and adjusted EBITDA. The update also highlighted CMS Medicare coverage support for key transplant tests and the completed divestiture/acquisition moves, all of which are favorable for the stock.
✅ Zacks Research Upgrades CareDx (NASDAQ:CDNA) to Strong-Buy — MarketBeat.
🤖 A research upgrade to Strong-Buy is supportive for sentiment and can attract buyers. The article also notes that broader consensus remains Hold, so the upside impact is positive but somewhat tempered.
⚪️ CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) — Yahoo Finance / Business Wire.
🤖 This is a routine equity-compensation announcement for a newly appointed executive advisor. It does not change the company’s operating outlook or provide material financial information, so it is neutral for CDNA.
⚪️ CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Recommendation of Hold from Analysts — MarketBeat.
🤖 The article summarizes mixed analyst views and a Hold consensus rather than a clear bullish or bearish catalyst. That makes it neutral for the stock price overall.
🍭 Bonus (B): 0/10 — Medical Laboratories

🏢 What they do: Ziff Davis is a digital media and internet company that operates a portfolio of online brands and services across technology, shopping, gaming, entertainment, health and wellness, connectivity, cybersecurity, and marketing technology.
- 🎯 Current $54.31 is 23% below 3yr high $70.84 · ⏳ SMA200 $41.23 (current price $54.31 is above) · 💰 Market Cap $1.9B
- ZD shows decent technicals supported by positive sentiment.

💎 Quality (Q): 50/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 2668% (>20%); ROE 29% (>15%); Low LT D/E 0.39 (<1.0); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 2/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 55 in healthy mid-range
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Ziff Davis Q2 2026 slides: EPS rises 13% as buybacks offset revenue slip — Investing.com.
🤖 Ziff Davis reported second-quarter 2026 results showing EPS growth and strong share repurchases, which helped offset weaker consolidated revenue. The market reacted favorably, with shares rising more than 10% after the presentation.
✅ Ziff Davis (NASDAQ:ZD) Releases Quarterly Earnings Results, Beats Estimates By $0.22 EPS — MarketBeat.
🤖 The company beat earnings expectations with EPS of $1.03 versus the $0.81 consensus, and revenue was roughly in line with estimates. Shares rose after the release, reinforcing a constructive near-term trading tone.
⚪️ Ziff Davis, Inc. (NASDAQ:ZD) Given Consensus Rating of "Hold" by Analysts — MarketBeat.
🤖 The broader analyst view remains mixed, with a consensus Hold rating and an average target near the current share price. This limits the immediate directional impact even though some firms have raised targets.
🍭 Bonus (B): 0/10 — Telegraph & Other Communications